Truist initiated coverage of Carlsmed (CARL) with a Buy rating and $18 price target The firm views Carlsmed as a high growth spine implant company with more predictable alignment and reduced revision rates. The company’s Aprevo is the first U.S. approved personalized spine implant utilizing an artificial intelligence algorithm to address traditional implant limitations, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CARL: